Medical articles today

/* 728x15, */

New Survey Shows Gap In Diagnosis And Treatment Of Osteoporosis Among Post-Menopausal Women Studied Who Were Hospitalized With Fractures

New results from a survey of 1, 122 post-menopausal women in Asia found that nearly half (48.5 percent) were not aware whether or not they had osteoporosis despite being hospitalized with a fragility fracture. A fragility fracture is one potential indicator of osteoporosis, along with BMD measurements, family history and other factors, according to International Osteoporosis Foundation (IOF). Of the women who were told that they have osteoporosis (51.5 percent), 40.5 percent did not receive any treatment. The results of this survey, which was conducted in Hong Kong SAR, Thailand, South Korea, mainland China, Singapore, Malaysia and Taiwan region, were presented at the 1st Scientific Meeting of the Asian Federation of Osteoporosis Societies.

The Mammalian System For Controlling Bone Remodelling Also Regulates Fever

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309). The work provided the fist genetic proof for a completely new and rational treatment for osteoporosis, one of the most serious public health problems for older women. The results of phase III clinical trials for a human antibody to RANKL have recently been published (see Cummings et al.

/* 468x60, */

Karo Bio Announces That Merck Co., Inc. Plans To Proceed With Phase II Clinical Evaluation Of Candidate Compound

The Swedish biotech company Karo Bio (Reuters: KARO.ST) announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development. The randomized, double-blind, placebo- and active-controlled study will assess the safety, tolerability, and efficacy of MK-6913 for the treatment of moderate-to-very-severe vasomotor symptoms (hot flashes/hot flushes) in postmenopausal women. It is estimated that 300 patients will be enrolled in the study.

Newer Drug Shows Better Survival Rates Than Tamoxifen For Postmenopausal Breast Cancer Patients

Postmenopausal women with breast cancer who are treated with the drug letrozole show increased survival rates after surgery compared with those treated with the drug tamoxifen, which is more widely used, according to a study published Thursday in the New England Journal of Medicine, HealthDay / U.S. News & World Report reports. According to HealthDay / U.S. News, both drugs are used to prevent the recurrence of breast cancer in postmenopausal women with hormone receptor-positive cancer by preventing the production or activity of estrogen. However, the drugs work differently, and it has been unclear whether one drug is better than the other.

Menopause-Cardiology Consensus Statement On Cardiovascular Disease And On HRT

A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. The International Menopause Society consensus statement was developed at a Workshop** between menopause specialists and cardiologists. The Task Force on Gender of the European Society of Cardiology participated in the Workshop. The statement was published in current issue of the peer-reviewed journal Climacteric. The main messages of the Workshop are: Many women and their doctors are unaware of the cardiovascular dangers facing women going through and after the menopause.

/* 468x60, */

Estrogen Supplements Not As Effective As Claimed

Dietary supplements claiming to help postmenopausal women with bone health may not be doing what they say, according to new research from Purdue University. "We found that some plant-derived isoflavones have a modest effect on suppressing bone loss during post-menopause, but more concerning is many dietary supplements that claim to have the power of estrogen do not, " said Connie Weaver, distinguished professor of foods and nutrition. "It's buyer beware. Some of the supplements in our study claimed to be substitutes for estrogen, yet they weren't effective at all or weren't as effective as some of the current treatments for osteoporosis." Women who are menopausal or postmenopausal produce less estrogen, and that leads to bone loss.

Fast: [10] [20]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy